A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

Clinical trial NCT05701423 · TERMINATED

Trial details

NCT number: NCT05701423
Sponsor: Biogen
Status: TERMINATED
Study type: OBSERVATIONAL

Multiple Sclerosis

Start date: 2023-02-08
Primary completion: 2024-07-31
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.